{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:41:53Z","timestamp":1783086113421,"version":"3.54.6"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.psychres.2026.117152","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:52:27Z","timestamp":1775145147000},"page":"117152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Psychedelics as a potential treatment for borderline personality disorder: A narrative review"],"prefix":"10.1016","volume":"361","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1797","authenticated-orcid":false,"given":"Erin","family":"Artna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guneet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-7951","authenticated-orcid":false,"given":"Orly","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7691","authenticated-orcid":false,"given":"Danica E","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-9942","authenticated-orcid":false,"given":"Saadia","family":"Sediqzadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2026.117152_bib0066","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2026.117152_bib0093","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0447.2004.00461.x","article-title":"Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum","volume":"110","author":"Akiskal","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2026.117152_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.psychres.2026.117152_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10673220600975121","article-title":"Borderline personality disorder, stigma, and treatment implications","volume":"14","author":"Aviram","year":"2006","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0097","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40479-022-00182-0","article-title":"The ICD-11 classification of personality disorders: a European perspective on challenges and opportunities","volume":"9","author":"Bach","year":"2022","journal-title":"bord personal disord emot dysregul"},{"key":"10.1016\/j.psychres.2026.117152_bib0062","article-title":"Intravenous ketamine for suicide ideation in borderline personality and depression","author":"Bachir","year":"2025","journal-title":"L\u2019Encephale"},{"key":"10.1016\/j.psychres.2026.117152_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/pmh.1368","article-title":"Barriers and facilitators to the implementation of mentalization-based treatment (MBT) for borderline personality disorder","volume":"11","author":"Bales","year":"2017","journal-title":"Personal. Ment. Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0033","first-page":"29","article-title":"Comorbidities in borderline personality disorder: real-world issues and treatment implications","volume":"30","author":"Biskin","year":"2013","journal-title":"Psychiatr. Times"},{"key":"10.1016\/j.psychres.2026.117152_bib0002","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/070674371506000702","article-title":"The lifetime course of borderline personality disorder","volume":"60","author":"Biskin","year":"2015","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"10.1016\/j.psychres.2026.117152_bib0089","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/NMD.0b013e31827f6435","article-title":"Systems training for emotional predictability and problem solving (STEPPS) group treatment for offenders with borderline Personality disorder","volume":"201","author":"Black","year":"2013","journal-title":"Journal of Nervous & Mental Disease"},{"key":"10.1016\/j.psychres.2026.117152_bib0099","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1037\/per0000698","article-title":"Identity disturbance in dimensional and categorical models of personality disorder: the incremental value of self-rated identity and narrative identity","volume":"15","author":"Bogaerts","year":"2024","journal-title":"Personal. Disord."},{"key":"10.1016\/j.psychres.2026.117152_bib0037","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.psychres.2026.117152_bib0044","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-021-01230-z","article-title":"Low dose oral ketamine treatment in chronic suicidality: an open-label pilot study","volume":"11","author":"Can","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0043","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.psychres.2026.117152_bib0039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0018","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10488-013-0504-6","article-title":"Barriers and solutions to implementing dialectical behavior therapy in a public Behavioral health system","volume":"41","author":"Carmel","year":"2014","journal-title":"Adm Policy Ment Health Ment Health Serv Res"},{"key":"10.1016\/j.psychres.2026.117152_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.890099","article-title":"Case report: effectiveness of brexpiprazole and esketamine\/ketamine combination: a novel therapeutic strategy in five cases of treatment-resistant depression","volume":"13","author":"Chan","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0013","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HRP.0000000000000113","article-title":"Evidence-based treatments for Borderline personality disorder: implementation, integration, and stepped care","volume":"24","author":"Choi-Kain","year":"2016","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamapsychiatry.2016.4287","article-title":"Efficacy of psychotherapies for Borderline Personality Disorder: a systematic review and meta-analysis","volume":"74","author":"Cristea","year":"2017","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2026.117152_bib0028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9740\/mhc.2017.01.024","article-title":"Clinical potential of psilocybin as a treatment for mental health conditions","volume":"7","author":"Daniel","year":"2017","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.psychres.2026.117152_bib0063","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bdi.13375","article-title":"Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: a case report","volume":"25","author":"de Filippis","year":"2023","journal-title":"Bipolar. Disord."},{"key":"10.1016\/j.psychres.2026.117152_bib0083","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6939-8-4","article-title":"Informed consent for research in Borderline Personality Disorder","volume":"8","author":"Dew","year":"2007","journal-title":"BMC. Med. Ethics"},{"key":"10.1016\/j.psychres.2026.117152_bib0076","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0046","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41386-023-01540-4","article-title":"A pilot randomized controlled trial of ketamine in Borderline Personality Disorder","volume":"48","author":"Fineberg","year":"2023","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.psychres.2026.117152_bib0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.copsyc.2021.01.002","article-title":"Dialectical behaviour therapy: implementation of an evidence-based intervention for borderline personality disorder in public health systems","volume":"37","author":"Flynn","year":"2021","journal-title":"Curr. Opin. Psychol."},{"key":"10.1016\/j.psychres.2026.117152_bib0094","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jad.2020.09.138","article-title":"Diagnostic accuracy of DSM-5 borderline personality disorder criteria: toward an optimized criteria set","volume":"279","author":"Fowler","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2026.117152_bib0047","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/15622975.2023.2227901","article-title":"Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: focus on impulsivity","volume":"24","author":"Ga\u0142uszko-W\u0119gielnik","year":"2023","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0059","doi-asserted-by":"crossref","first-page":"44","DOI":"10.64719\/pb.4534","article-title":"Electroconvulsive therapy, ketamine, and esketamine in a patient with major depressive disorder and multiple comorbidities: a case report over 10-year treatment from adolescence to adulthood","volume":"55","author":"Gao","year":"2025","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2026.117152_bib0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","article-title":"Pharmacological treatments for Borderline Personality disorder: a systematic review and meta-analysis","volume":"35","author":"Gartlehner","year":"2021","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.psychres.2026.117152_bib0026","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.psychres.2026.117152_bib0064","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archgenpsychiatry.2011.37","article-title":"Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study","volume":"68","author":"Gunderson","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0042","doi-asserted-by":"crossref","unstructured":"Guss J., Krause R., Sloshower J. The Yale Manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame) 2020. https:\/\/doi.org\/10.31234\/osf.io\/u6v9y.","DOI":"10.31234\/osf.io\/u6v9y"},{"key":"10.1016\/j.psychres.2026.117152_bib0086","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/jopy.12811","article-title":"Combining novel trait and neurocognitive frameworks to parse heterogeneity in borderline personality disorder","volume":"91","author":"Hanegraaf","year":"2023","journal-title":"J. Pers."},{"key":"10.1016\/j.psychres.2026.117152_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1327598","article-title":"Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety","volume":"15","author":"Hauser","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2026.117152_bib0038","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.psychres.2026.117152_bib0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/NMD.0000000000000235","article-title":"Comorbid bipolar disorder and borderline personality disorder and substance use disorder","volume":"203","author":"Hidalgo-Mazzei","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.psychres.2026.117152_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/02791072.2022.2044096","article-title":"The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: a systematic review","volume":"55","author":"Hodge","year":"2023","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.psychres.2026.117152_bib0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1556\/2054.2020.00128","article-title":"A potential role for psilocybin in the treatment of obsessive-compulsive disorder","volume":"4","author":"Jacobs","year":"2020","journal-title":"J. Psychedelic. Stud."},{"key":"10.1016\/j.psychres.2026.117152_bib0077","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12888-023-05365-9","article-title":"Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2])","volume":"23","author":"Jelovac","year":"2023","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0029","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117152_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036517","article-title":"Recovery in Borderline Personality disorder (BPD): a qualitative study of service users\u2019 Perspectives","volume":"7","author":"Katsakou","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.psychres.2026.117152_bib0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jad.2023.02.034","article-title":"Suicidal urges and attempted suicide at multiple time scales in borderline personality disorder","volume":"329","author":"Kaurin","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"95","key":"10.1016\/j.psychres.2026.117152_bib0049","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.biopsych.2024.02.374","article-title":"Ketamine\u2019s efficacy in suicidal depressed patients with borderline personality disorder","volume":"139","author":"Keilp","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0032","series-title":"Disruptive Psychopharmacol","first-page":"319","article-title":"Psilocybin for trauma-related disorders","author":"Khan","year":"2022"},{"key":"10.1016\/j.psychres.2026.117152_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0924-9338(15)30162-0","article-title":"A nationwide study of mortality in patients with borderline personality disorder","volume":"30","author":"Kj\u00e6r","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0098","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000508538","article-title":"An overview of the DSM-5 Alternative model of Personality disorders (AMPD)","volume":"53","author":"Krueger","year":"2020","journal-title":"Psychopathology."},{"key":"10.1016\/j.psychres.2026.117152_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029108","article-title":"Effects of ketamine treatment on suicidal ideation: a qualitative study of patients\u2019 accounts following treatment for depression in a UK ketamine clinic","volume":"9","author":"Lascelles","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.psychres.2026.117152_bib0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/wps.21156","article-title":"Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies","volume":"23","author":"Leichsenring","year":"2024","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0074","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11920-019-1108-y","article-title":"Suicide has many faces, so does Ketamine: a narrative review on Ketamine\u2019s antisuicidal actions","volume":"21","author":"Lengvenyte","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.psychres.2026.117152_bib0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/pmh.1183","article-title":"Borderline personality disorder subtypes: a factor analysis of the DSM-IV criteria","volume":"6","author":"Lewis","year":"2012","journal-title":"Personality & Mental Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1416420","article-title":"Psilocybin for major depressive disorder: a systematic review of randomized controlled studies","volume":"15","author":"Li","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0056","article-title":"Very low-dose sublingual ketamine for borderline personality disorder and treatment-resistant depression","volume":"16","author":"Liester","year":"2024","journal-title":"Cureus."},{"key":"10.1016\/j.psychres.2026.117152_bib0051","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S1092852920002102","article-title":"Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence","volume":"27","author":"Lipsitz","year":"2022","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.psychres.2026.117152_bib0021","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41591-021-01530-3","article-title":"Psychedelic therapy: a roadmap for wider acceptance and utilization","volume":"27","author":"Marks","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.psychres.2026.117152_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.9740\/mhc.2016.03.62","article-title":"Dialectical behavior therapy as treatment for borderline personality disorder","volume":"6","author":"May","year":"2016","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.psychres.2026.117152_bib0004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11920-023-01440-w","article-title":"Suicide Risk in Personality disorders: a systematic review","volume":"25","author":"McClelland","year":"2023","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.psychres.2026.117152_bib0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12888-018-1802-z","article-title":"The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: the feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol","volume":"18","author":"McMain","year":"2018","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0027","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/psychoactives4030020","article-title":"Ketamine and esketamine in psychiatry: a comparative review emphasizing neuroplasticity and clinical applications","volume":"4","author":"Mikellides","year":"2025","journal-title":"Psychoactives"},{"key":"10.1016\/j.psychres.2026.117152_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1176\/appi.psychotherapy.2015.69.2.91","article-title":"Introduction to a special issue Dialectical Behavior Therapy: evolution and adaptations in the 21st century","volume":"69","author":"Miller","year":"2015","journal-title":"Am. J. PsychOther"},{"key":"10.1016\/j.psychres.2026.117152_bib0057","article-title":"Esketamine\u201d in Borderline Personality disorder: a look beyond suicidality","volume":"14","author":"Nandan","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.psychres.2026.117152_bib0019","series-title":"Borderline Personality Disorder: Treatment and Management","year":"2009"},{"key":"10.1016\/j.psychres.2026.117152_bib0078","unstructured":"Clinical review report: esketamine hydrochloride (Spravato): (Janssen Inc.): indication: major depressive disorder in adults 2021."},{"key":"10.1016\/j.psychres.2026.117152_bib0072","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0269881113486718","article-title":"Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive\u2013compulsive disorder and a history of major depressive disorder","volume":"27","author":"Niciu","year":"2013","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.psychres.2026.117152_bib0065","article-title":"Targeting inflammation in depression: ketamine as an anti-inflammatory antidepressant in psychiatric emergency","volume":"18","author":"Nikkheslat","year":"2021","journal-title":"Brain Behav Immun - Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0068","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/ph18040555","article-title":"The emergence of psilocybin in psychiatry and neuroscience","volume":"18","author":"Omidian","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.psychres.2026.117152_bib0079","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1037\/pst0000551","article-title":"A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers","volume":"62","author":"Palitsky","year":"2025","journal-title":"Psychotherapy"},{"key":"10.1016\/j.psychres.2026.117152_bib0052","article-title":"Predictors of response to intranasal ketamine in patients hospitalized for treatment-resistant depression","volume":"43\u201344","author":"Peters","year":"2024","journal-title":"Pers. Med. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/IJPSYM.IJPSYM_132_17","article-title":"Empirical reality of dialectical behavioral therapy in borderline personality","volume":"39","author":"Reddy","year":"2017","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.psychres.2026.117152_bib0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JCP.0000000000001642","article-title":"Ketamine as a treatment option for severe borderline personality disorder: a case report","volume":"43","author":"Rogg","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117152_bib0082","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1097\/MS9.0000000000003232","article-title":"Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review","volume":"87","author":"Sayad","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.psychres.2026.117152_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.3869","article-title":"A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression","volume":"9","author":"Schwartz","year":"2021","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.psychres.2026.117152_bib0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12911-016-0405-1","article-title":"Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database","volume":"17","author":"Shen","year":"2017","journal-title":"BMC. Med. Inform. Decis. Mak."},{"key":"10.1016\/j.psychres.2026.117152_bib0084","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192113792","article-title":"A pilot study of ketamine infusion after suicide attempt: new frontiers in treating acute suicidality in a real-world medical setting","volume":"19","author":"Shivanekar","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0087","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/2167702618769560","article-title":"Identifying core deficits in a dimensional model of borderline Personality disorder features: a network analysis","volume":"6","author":"Southward","year":"2018","journal-title":"Clin. Psychol. Sci."},{"key":"10.1016\/j.psychres.2026.117152_bib0096","doi-asserted-by":"crossref","first-page":"e9635","DOI":"10.32872\/cpe.9635","article-title":"Personality disorder Diagnoses in ICD-11: transforming conceptualisations and practice","volume":"4","author":"Swales","year":"2022","journal-title":"Clin. Psychol. Eur."},{"key":"10.1016\/j.psychres.2026.117152_bib0075","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.2147\/NDT.S198804","article-title":"Borderline personality disorder, trauma, and the hypothalamus\u2013pituitary\u2013adrenal axis","volume":"15","author":"Thomas","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2026.117152_bib0007","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12888-019-2377-z","article-title":"Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice","volume":"19","author":"Tim\u00e4us","year":"2019","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0088","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1521\/pedi_2012_26_093","article-title":"Characteristics of borderline Personality disorder in a community sample: comorbidity, treatment utilization, and general functioning","volume":"28","author":"Tomko","year":"2014","journal-title":"J Personal Disord"},{"key":"10.1016\/j.psychres.2026.117152_bib0091","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11126-025-10141-x","article-title":"Underlying dimensions of Borderline Personality disorder: a systematic Review of Factor Analytic studies","volume":"96","author":"Triantafyllou","year":"2025","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.psychres.2026.117152_bib0023","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: a re-emerging therapeutic paradigm","volume":"187","author":"Tupper","year":"2015","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"10.1016\/j.psychres.2026.117152_bib0092","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/pmh.78","article-title":"Why borderline personality disorder is neither borderline nor a personality disorder","volume":"3","author":"Tyrer","year":"2009","journal-title":"Personality & Mental Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0058","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/15622975.2022.2031287","article-title":"Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder","volume":"23","author":"Vanicek","year":"2022","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues. Clin. Neurosci."},{"key":"10.1016\/j.psychres.2026.117152_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.927984","article-title":"Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders","volume":"13","author":"Vorobyeva","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2026.117152_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12888-021-03670-9","article-title":"Towards optimal treatment selection for borderline personality disorder patients (BOOTS): a study protocol for a multicenter randomized clinical trial comparing schema therapy and dialectical behavior therapy","volume":"22","author":"Wibbelink","year":"2022","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0034","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s40814-021-00915-y","article-title":"Factors affecting participant recruitment and retention in borderline personality disorder research: a feasibility study","volume":"7","author":"Woo","year":"2021","journal-title":"Pilot. Feasibility. Stud."},{"key":"10.1016\/j.psychres.2026.117152_bib0073","article-title":"Comparing the adverse effects of ketamine and esketamine between genders using FAERS data","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2026.117152_bib0067","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11126-020-09871-x","article-title":"Adverse effects of esketamine for the treatment of major depression disorder: findings from randomized controlled trials","volume":"93","author":"Yang","year":"2022","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.psychres.2026.117152_bib0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"10.1016\/j.psychres.2026.117152_bib0069","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.psychres.2026.117152_bib0061","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1521\/pedi.2025.39.2.170","article-title":"Ketamine-assisted psychotherapy for treatment of Co-occurring borderline personality disorder and depression: a case study","volume":"39","author":"Yeung","year":"2025","journal-title":"J Personal Disord"},{"key":"10.1016\/j.psychres.2026.117152_bib0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/10503307.2022.2138790","article-title":"Investigating predictors of treatment response in Dialectical Behavior Therapy for borderline personality disorder using LASSO regression","volume":"33","author":"Yin","year":"2023","journal-title":"PsychOther Res."},{"key":"10.1016\/j.psychres.2026.117152_bib0016","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1521\/pedi.2005.19.5.505","article-title":"The McLean Study of adult development (MSAD): overview and implications of the first six years of prospective follow-up","volume":"19","author":"Zanarini","year":"2005","journal-title":"J Personal Disord"},{"key":"10.1016\/j.psychres.2026.117152_bib0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1176\/ajp.2007.164.6.929","article-title":"The subsyndromal phenomenology of Borderline Personality disorder: a 10-year follow-up study","volume":"164","author":"Zanarini","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117152_bib0081","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","article-title":"Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up","volume":"35","author":"Zanarini","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117152_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcbs.2019.11.001","article-title":"Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder","volume":"15","author":"Zeifman","year":"2020","journal-title":"J Context Behav Sci"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:09:13Z","timestamp":1782565753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":99,"alternative-id":["S0165178126002131"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117152","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics as a potential treatment for borderline personality disorder: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117152"}}